Navigation Links
Genotype in Biological Technology

Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study

... interferon. The study in treatment naive genotype 1 infected subjects was of standard design, ... open-label study in 278 treatment-naive, genotype 1 patients evaluating taribavirin at weight-based ... disclosed as Study 204), 278 treatment naive, genotype 1 patients were randomized with the following ...

Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights

... at 800 mg bid, 2.9 log10 (range of 2.2 to 3.4). genotype 1a patients demonstrated median reductions of 1.4 ... 400 and 800 mg bid, respectively. In 10 of the 12 genotype 1a patients who received ANA598, viral load was ... at the end of the three days of treatment. genotype 1b patients demonstrated median reductions of 2.6 ...

INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients

... 14 days in treatment-experienced patients with genotype 1 HCV infection who have been previously treated ... F consists of null responder HCV patients with genotype 1 infection who have been treated with pegylated ... patients chronically infected with HCV genotype 1. The original study protocol consisted of four ...

Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan

... of hepatitis C virus (HCV) replication in HCV genotype 1-derived replicon cell lines, and in vitro ... with chronic hepatitis C infected with HCV genotype 4. Phase II clinical trials are ongoing in the United States in patients with HCV genotype 1. About Romark Laboratories Romark ...

Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C

... in treatment-naive patients infected with HCV genotype 4, 82% (n=17) and 100% (n=16) of patients ... activity in a small number of patients with HCV genotype 4. We look forward to reporting interim data from ... tablet in patients with chronic hepatitis C genotype 1 later this year." In the Phase I study, ...

Pharmasset Reports Fiscal First Quarter 2009 Financial Results

... day add-on study with R7128 in non-responder, HCV genotype 2 and genotype 3 patients in first half of 2009; -- Report ... add-on study with R7128 in treatment naive, HCV genotype 1 patients in first half of 2009; -- Report ...

Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients

... enroll about 400 treatment naive, genotype-1 or genotype 4 HCV-infected patients. The trial will evaluate ... patients chronically infected with HCV genotype 1, R7128 demonstrated significant short-term ... in 81 treatment-naive patients infected with HCV genotype 1 indicated: Results with ...

Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting

... laboratory test which determines haptoglobin genotype may be useful in selecting and guiding patient ... clinics in Israel underwent haptoglobin genotype testing and were randomized to receive either ... it was determined that those who had the Hp2-2 genotype and who also received vitamin E had ...

Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association

... a new clinical test to determine haptoglobin (Hp) genotype utilizing intellectual property licensed from Synvista is now available. Knowledge of Hp genotype may help physicians to assess cardiovascular risk ... individuals with diabetes mellitus and the Hp2-2 genotype (Hp2-2 Diabetes) demonstrate a significantly ...

Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008

... nitazoxanide and peginterferon in genotype 4 patients and provide a first look at sustained ... In this Phase II study, 44 patients (40 with HCV genotype 4; 3 with HCV genotype 1; and 1 with HCV genotype 2) received 4 weeks of nitazoxanide 500 mg twice ...

GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology

... is particularly positioned for use in HCV genotype 1 which has become the predominant genotype worldwide and which is the most difficult to treat, as well as in patients infected with HCV genotype 3 because of the following properties: - ...

InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting

... of treatment-naive patients infected with HCV genotype 1. Multiple ascending doses were examined up to a ... 14 days to strictly defined non-responders: HCV genotype 1 patients who had failed to achieve a 2.0 log10 ... Treatment of Chronic Hepatitis C Virus (HCV) genotype 1 Patients with the NS3/4A Protease Inhibitor ...

Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders

... - 90% of genotype 2 or 3 patients achieve undetectable HCV RNA ... chronically infected with hepatitis C virus (HCV) genotype 2 or 3 who had not achieved a Sustained Viral ... demonstrated significant antiviral activity in genotype 2 or 3 patients who had failed ...

Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales

... it has been established that the Haptoglobin genotype is an independent risk factor for cardiovascular ... in people with both diabetes and the Hp 2-2 genotype (approximately 40 percent of all diabetes ... diagnostic test to determine haptoglobin genotype in order to identify the subset of diabetics at ...

Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study

... prior non-responders and R7128 1000mg BID in HCV genotype 1 treatment-naive patients ... 1000mg BID in treatment-naive patients with HCV genotype 1. This cohort is intended to provide clinical ... patients chronically infected with HCV genotype 1 will be presented at the 43rd Annual Meeting of ...

Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States

... in 60 patients with chronic hepatitis C genotype 1 who have failed to respond to standard therapy ... and naive patients with chronic hepatitis C genotype 4, is a phase II randomized controlled trial ... States in 60 patients with chronic hepatitis C genotype 1 who have previously failed to respond to ...

Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients

... within the next several weeks. In the Phase II study, naive genotype 1 patients will receive ANA598 or placebo in combination with Pegasys(R) ... antiviral activity and good tolerability. In a monotherapy study in naive genotype 1 patients, treatment with ANA598 for three days led to median declines in ...

ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection

... a Phase Ib study of ANA598 in HCV patients. In the Phase Ib study, naive genotype 1a and 1b patients are to receive ANA598 over three days at doses of 200 ... Inadequate response rates, in particular for patients infected with genotype 1 HCV, along with significant side effects of approved therapy, support ...

Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco

... trial to evaluate nitazoxanide for the treatment of chronic hepatitis C genotype 1 (STEALTH C-3). The STEALTH C-3 (Studies to Evaluate Alinia for Treatment ... Roche) in treatment naive patients with chronic hepatitis C infected with genotype 1. The primary objective of this trial is to evaluate sustained virologic ...

Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes

... and unfavorable (13%). In the study, patients with the very favorable genotype experienced significant improvements in clinical endpoints compared to ... While the most robust clinical effects occurred in the very favorable genotype group, patients with the favorable genotype also benefitted from treatment ...

Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments

... - Albuferon(R) Phase 3 trial in genotype 1 hepatitis C completes treatment phase - - ... ACHIEVE 2/3 in April 2008. ACHIEVE 1 is being conducted in patients with genotype 1 chronic hepatitis C; ACHIEVE 2/3 is being conducted in patients with ...

MIGENIX Corporate Update and Requisition of Special Meeting

... drugs alone for up to 12 weeks of therapy in treatment-naive HCV infected genotype 1 patients is in the final stages of completion. Results from the study ... in the next several weeks. A previous Phase II study in non-responder genotype 1 patients provided proof of concept in that HCV patient population (see ...

MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study

... a satisfactory outcome for approximately 50% of patients infected with HCV genotype 1 (the most prevalent genotype in North America). About MIGENIX MIGENIX is committed to advancing ...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

... study of ANA598 in combination with pegylated interferon-alpha and ribavirin for the treatment of chronic hepatitis C. In the Phase II study, naive genotype 1 patients will receive ANA598 or placebo in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin, USP) (a current standard ...

Atherotech Taps Canyons Medical Center Director, Lipidologist as Chief Medical Officer

... For." The company also provides more than a dozen cardiovascular and metabolic testing panels, including C-Reactive Protein (hsCRP), ApoE genotype and NT-proBNP for assessment of patients at intermediate to high risk of cardiometabolic diseases. Atherotech continues to add advanced and follow-up ...

Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease

... may produce lasting effects in those patients with this combination of genotypic markers. The combination of the E4(-); IDE_7(C/C)(-) genotype is prevalent in approximately 40% of the AD population, so the number of potential responder patients is substantial. "This pharmacogenomic ...

Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598

... intends to initiate the trial during the third quarter of 2009. The current protocol design calls for 12 weeks of dosing ANA598 in naive genotype 1 patients in combination with SOC, compared to a control arm that will receive a placebo and SOC. After 12 weeks, patients are expected to continue ...

Pharmasset Reports Fiscal Second Quarter 2009 Financial Results

... that its development partner, Roche, had initiated dosing of patients in the phase 2b trial of R7128 in combination with the standard of care in genotype 1 and 4 HCV infected patients. The start of the trial triggered a $10.0 million milestone payment to Pharmasset that is expected to be received in ...

Avian Adenovirus Genotyping Diagnostic Service

... use of boot strapping analysis on extended genetic sequences allows the investigator to arrive at statistically significant conclusions regarding the genotype of a strain and its association with another strain. Thus the technology is ideally suited to determine if an adenovirus isolated from one flock is ...

Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments

... endpoint of non-inferiority to Pegasys (peginterferon alfa-2a) in ACHIEVE 1, a Phase 3 clinical trial of Albuferon in treatment-naive patients with genotype 1 chronic hepatitis C. As previously reported, Albuferon also met its primary endpoint in ACHIEVE 2/3, which was conducted in treatment-naive ...

InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting

... and Ribavirin in Patients with Chronic Hepatitis C Virus (HCV). Incidence of Virologic Escape Observed During ITMN-191 Monotherapy is genotype Dependent, Associated with a Specific NS3 Substitution, and Suppressed Upon Combination with Peginterferon alfa-2a/Ribavirin . ...

Human Genome Sciences to Sponsor Conference Call

... that it will sponsor a conference call to discuss the results of its ACHIEVE 1 Phase 3 trial of Albuferon(R) (albinterferon alfa-2b) in patients with genotype 1 chronic hepatitis C. (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) The conference call will be hosted by senior ...

Pigs to Be Genotyped to Improve Selection and Breeding for Pancreatic Islet Cell Research

... that are naturally superior donors of pancreatic islet tissue for diabetes cure. GeneSeek will take samples from Spring Point Project's pigs to genotype for over 60,000 DNA markers using the new Infinium HD Porcine SNP60 Bead Chip from Illumina, Inc. (San Diego, CA). This will provide Spring Point ...

Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C

... further analysis. We look forward to results from the ACHIEVE 1 trial, which is evaluating albinterferon alfa-2b in the treatment of patients with genotype 1 hepatitis C." In the randomized, multi-center, active-controlled non-inferiority Phase 3 trial, 933 treatment-naive patients with ...

InterMune Reports Third Quarter 2008 Financial Results and Business Highlights

... antiviral compounds when used in monotherapy for 14 days in treatment-naive patients chronically infected with hepatitis C virus (HCV) genotype 1. - Excellent safety and tolerability for ITMN-191 in all dosage regimens. - The in-vitro combination of ITMN-191 with the active ...

Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients

... current standard of care is a combination of pegylated interferon and ribavirin. Inadequate response rates, in particular for patients infected with genotype 1 HCV, along with significant side effects of approved therapy support the medical need for improved treatment options. It is estimated that fewer ...

Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights

... for the treatment of hepatitis C virus (HCV) infection, and expects to initiate patient dosing shortly. ANA598 will be administered to naive genotype 1a and 1b patients at 200 mg bid (twice-a-day), 400 mg bid or 800 mg bid over a period of three days. Anadys expects to have viral load data from ...

FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma

... mortality, heart failure hospitalization, and cardiovascular hospitalization. While the most robust clinical effects occurred in the very favorable genotype group, patients with the favorable genotype also benefited from treatment with bucindolol. Bucindolol also demonstrated clinically significant ...

As personalized, genomic medicine takes off, four developing countries show the way for others

... and linguistic subpopulations. Meanwhile, an Indian life-sciences company, Avesthagen Ltd, has announced a five-year, $32 million project to genotype the country's entire Parsi population -- about 69,000 people. The Parsis, thought to be genetically homogenous, are feared to be at risk owing to ...

Synvista Therapeutics Posts Letter to Stockholders on Web Site

... research, development and marketing. DIAGNOSTICS We believe that we have a clear development pathway for our immunoassay test to determine the 2-2 genotype of Hp and have validated the accuracy of a commercial kit, as presented at the 2008 Cardiovascular Biomarkers and Surrogate Endpoints Symposium in ...
Other Contents
(Date:4/23/2014)... pair of bioethics experts have added "playwright" to their ... in grappling with an onslaught of ethical issues as ... the human genome was first sequenced. , Until ... W. Bush have been performed for, and by, their ... conferences, meetings and in classrooms. With Oxford University ...
(Date:4/23/2014)... Wash. -- Like a hungry diner ripping open a ... into electricity must tear open a hydrogen molecule. Now ... holding onto the two halves of its hydrogen feast. ... how to make the catalyst work better for alternative ... scientists have shown precisely where the hydrogen halves end ...
(Date:4/23/2014)... evidence that the source of a unique rhythmic sound, ... the "bio-duck," is the Antarctic minke whale ( Balaenoptera ... in the 1960s who thought it sounded like a ... locations in the Southern Ocean, but its source has ... an international team of researchers deployed acoustic tags on ...
Breaking Biology News(10 mins):Bioethicists use theatrical narratives to bridge the gap between society and science 2Bioethicists use theatrical narratives to bridge the gap between society and science 3Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Scientists identify source of mysterious sound in the Southern Ocean 2Scientists identify source of mysterious sound in the Southern Ocean 3
(Date:4/24/2014)... long thought to be boring and irrelevant, could offer ... disease. , Researcher Dr Milena Furtado, and her team ... University, found the heart cell fibroblast is a close ... healthy beating heart. , In research published today in ... cardiac fibroblasts are unique cells due to their genetic ...
(Date:4/24/2014)... one out of three survivors of critical illness, ... The Lancet Respiratory Medicine , and the majority ... mentally. , It is one of the largest ... outcomes of critical care survivors, according to lead ... and it highlights a significant public health issue, ...
(Date:4/24/2014)... NH, 4/24/14) Dartmouth has been awarded one of ... serve as a Lead Academic Participating Site in its ... Award recipients are a select groups of investigators charged ... fewer cooperative groups., The NCTN grant system reflects recommendations ... It streamlines operations to achieve four goals:, ...
(Date:4/24/2014)... In 2009 the influenza pH1N1 virus caused the first ... Finland in May 2009 and killed more than 50 ... infects Finns mainly during flu epidemics (winter/spring seasons). ... to serious complicated illnesses. World Health Organization has recommended ... illness. The disadvantage of this drug is that it ...
(Date:4/23/2014)... was safe and effective in treating patients with ... , according to a new pilot study published ... online. Known as fecal microbiota transplantation, the treatment ... or a nasogastric tube. The findings suggest approaches ... available to patients. , A growing concern, ...
Breaking Medicine News(10 mins):Health News:Boring cells could hold the key to heart disease 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2
Other TagsOther Tags